DULA
Dulaglutide (marketed as Trulicity) is an FDA-approved once-weekly GLP-1 receptor agonist for type 2 diabetes. It consists of a GLP-1 analog fused to a modified immunoglobulin Fc fragment for extended duration.
Regulatory status (as of Sept 2026)
FDA-approved (Trulicity) for T2DM glycemic control and MACE risk reduction; carries boxed warning for thyroid C-cell tumors.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote9 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
Dulaglutide is an FDA-approved prescription drug. Dulaglutide (marketed as Trulicity) is an FDA-approved once-weekly GLP-1 receptor agonist for type 2 diabetes.
| Half-life | About 5 days |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | FDA-approved |
| Dosing | Published research: 0.75, 1.5 mg weekly (REWIND used 1.5 mg SC weekly) details0.75, 1.5 mg weekly (REWIND used 1.5 mg SC weekly); AWARD-11 tested 1.5, 3.0, 4.5 mg weekly with 0.75 mg start.Community-reportedCommunity-reported: 0.75–4.5 mg once weekly, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It copies the gut hormone GLP-1, which helps the body release insulin when blood sugar is high and slows how fast the stomach empties. Proposed mechanism (GLP-1 receptor agonist pharmacology): activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon release and slow gastric emptying. The Fc fragment extends its half-life through FcRn-mediated recycling and reduced renal clearance. Its clinical effects come from the trials cited below (e.g. REWIND, Gerstein 2019).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedCommonly reported doses range from 0.75 to 4.5 mg once weekly (subcutaneous injection). This is not a recommendation.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
Dulaglutide (Trulicity) is a long-acting GLP-1 receptor agonist developed by Eli Lilly, approved by the FDA in 2014 for type 2 diabetes. The molecule is a fusion protein consisting of two copies of a modified GLP-1(7-37) analog linked to a modified human IgG4 Fc fragment via a small peptide linker. The REWIND cardiovascular outcomes trial was landmark — it was the first GLP-1 agonist trial to show cardiovascular benefit (MACE HR 0.88, 95% CI 0.79-0.99, median 5.4 years) in a population where most participants did not have established cardiovascular disease.
GLP-1(7-37) analog (A8G, G22E, R36G) x 2, fused to modified IgG4 Fc
Molecular Weight: ~63,000 Da (fusion protein)
Structure Details: Fusion protein consisting of two copies of a DPP-4 resistant GLP-1 analog each linked via a small peptide linker to a modified human IgG4-Fc heavy chain. The Fc portion is modified to reduce Fc-gamma receptor binding.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| Dulaglutide | ~5 days | Subcutaneous injection | FDA-approved |
| 5-Amino-1MQ | Unknown | Oral | Preclinical (animal) |
| AOD-9604 | No published PK data found | Subcutaneous injection | Discontinued |
| Adipotide (FTPP) | No published PK data found | Subcutaneous injection | Preclinical (animal) |
| Exenatide | 2.4 hours (immediate-release) | Subcutaneous injection | FDA-approved |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Metabolic category. View All Metabolic Peptides
Research
From Our Affiliated Clinic
1836 Wellness offers physician-supervised medical weight loss in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
Learn about medical weight loss →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.